PP 1: Selective Src Family Tyrosine Kinase Inhibitor for Cancer and Immunology Research

Executive Summary. PP 1 (CAS 172889-26-8) is a potent small molecule inhibitor that targets Src family tyrosine kinases, notably Lck (IC₅₀ = 5 nM) and Fyn (IC₅₀ = 6 nM) (APExBIO). Src family kinases are central to pathways controlling cell proliferation, migration, adhesion, and survival (Song et al., 2025). PP 1 demonstrates selective inhibition of Lyn kinase in RBL-2H3 cells, sparing Syk kinase, and blocks RET oncogene-driven transformation at nanomolar concentrations. In vivo, it reduces tyrosine phosphorylation and T-cell proliferation, making it a valuable tool for oncology and immunology research. The compound is supplied in solid form with a purity of 96.03%, is soluble in DMSO and ethanol, and is available from APExBIO (product page).

Biological Rationale

Src family tyrosine kinases (SFKs) are non-receptor protein kinases implicated in oncogenic transformation, tumor progression, and immune cell signaling (Song et al., 2025). In human cancer, overactive SFK signaling drives cell proliferation, migration, and metastasis. Lck and Fyn are crucial for T-cell activation and immune modulation. RET oncogene activation also relies on SFK pathways. Inhibiting SFKs with a selective agent like PP 1 enables researchers to dissect these pathways without broad off-target effects. Such selectivity is essential for accurate modeling of tumor biology or immune function (see also: Translational Oncology resource; this article details mechanistic precision and extends benchmarking data for PP 1).

Mechanism of Action of PP 1 (Src family tyrosine kinase inhibitor)

PP 1 is a synthetic pyrazolopyrimidine derivative (1-tert-butyl-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-4-amine) that competitively inhibits the ATP-binding site of Src family kinases. The compound exhibits nanomolar inhibition constants for Lck (IC₅₀ = 5 nM) and Fyn (IC₅₀ = 6 nM) in enzymatic assays at 25°C in standard kinase buffer. In cell-based assays, PP 1 selectively suppresses Lyn kinase activity in RBL-2H3 cells at concentrations as low as 10 nM, with no significant effect on Syk kinase at up to 1 μM. PP 1 also inhibits RET oncogene-driven transformation in NIH-3T3 cells at 30–100 nM. In vivo, administration of PP 1 reduces phosphorylation of tyrosine residues in immune tissues and suppresses T-cell proliferation, confirming its activity in animal models (APExBIO).

Evidence & Benchmarks

• PP 1 inhibits Lck kinase with an IC₅₀ of 5 nM and Fyn kinase with an IC₅₀ of 6 nM in vitro kinase assays (product docs).
• Selective suppression of Lyn kinase, but not Syk kinase, in RBL-2H3 cells at 10–100 nM PP 1 (product docs).
• PP 1 blocks RET oncogene-mediated cell transformation at 30–100 nM in NIH-3T3 fibroblasts (product docs).
• In vivo, PP 1 reduces tyrosine phosphorylation and T-cell proliferation in mouse models at administered doses of 2–10 mg/kg (product docs).
• Src family kinases are established drivers of oncogenic signaling and therapy resistance in prostate cancer and other tumors (Song et al., 2025).

Applications, Limits & Misconceptions

PP 1 is widely used as a tool compound for dissecting Src kinase pathways in oncology and immunology. It is employed in cell viability, proliferation, cytotoxicity, and signal transduction assays. Major applications include studying T cell activation, RET oncogene signaling, and cancer cell migration. Its high selectivity for Lck and Fyn enables targeted modulation of immune cell signaling and oncogenic pathways (compare: cell assay protocols and troubleshooting; this article expands on advanced in vivo applications and compound handling).

Common Pitfalls or Misconceptions

• PP 1 is not effective against receptor tyrosine kinases or non-Src kinases such as Syk, Abl, or EGFR at recommended concentrations.
• Long-term solution storage is not recommended; PP 1 degrades in aqueous buffers and should be freshly prepared.
• It is insoluble in water; use DMSO or ethanol as solvents for stock solutions.
• In vivo dosing must be carefully controlled; high concentrations may cause non-specific effects or toxicity.
• PP 1 does not distinguish between all Src family members; although Lck and Fyn are most sensitive, Hck, Lyn, and Yes kinase inhibition may occur at higher concentrations.

Workflow Integration & Parameters

PP 1 is supplied as a solid by APExBIO, with a molecular weight of 281.36 g/mol and a purity of 96.03%, accompanied by HPLC, MS, and NMR data (the A8215 kit). For in vitro studies, dissolve in DMSO (≥7.03 mg/mL) or ethanol (≥20.6 mg/mL with ultrasonic assistance). Stock solutions should be prepared fresh and stored desiccated at 4°C; long-term storage of solutions is not recommended. Typical working concentrations range from 1 nM to 1 μM for cell-based assays. In vivo dosing protocols vary, but effective inhibition is observed at 2–10 mg/kg in mice. Shipping is on blue ice; store desiccated upon receipt. For further workflow and protocol details, see this radiopathomics and biomarker integration resource, which this article extends by detailing compound stability and in vivo application caveats.

Conclusion & Outlook

PP 1 stands as the benchmark selective Src family tyrosine kinase inhibitor for cancer and immunology research. Its nanomolar potency for Lck and Fyn, robust selectivity, and proven in vitro and in vivo utility enable precise dissection of oncogenic and immune signaling pathways. By targeting critical drivers of cell proliferation and metastasis, PP 1 supports the development of next-generation cancer therapies and immune modulators. APExBIO supplies PP 1 with quality documentation, making it a reliable tool for laboratory and translational science. Ongoing research continues to clarify the roles of Src kinases in tumor progression and immune regulation, with PP 1 remaining a foundational reagent for these discoveries. For a broader perspective on translational strategy and resistance mechanisms, see this strategy article, which this piece updates with new evidence and workflow recommendations.